Keminterpharm Spechem Resources Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 09-01-2025
- Paid Up Capital ₹ 0.10 M
as on 09-01-2025
- Company Age 20 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 M
as on 09-01-2025
- Revenue 1301.45%
(FY 2020)
- Profit 4346.67%
(FY 2020)
- Ebitda 1380.54%
(FY 2020)
- Net Worth 168.61%
(FY 2020)
- Total Assets 396.42%
(FY 2020)
About Keminterpharm Spechem Resources
The Corporate was formerly known as Kiran Light Laboratories Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.50 M.
Kiran Oza and Rekha Oza serve as directors at the Company.
- CIN/LLPIN
U24100MH2004PTC146526
- Company No.
146526
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 May 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Keminterpharm Spechem Resources Private Limited offer?
Keminterpharm Spechem Resources Private Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Industrial Chemicals, Nutraceuticals & Dietary Supplements, Mineral Supplement, Insecticides and Pesticides, Plant Growth Regulators, Fertilizers and Soil Additives, Fertilizer, Acaricide, Chemical Intermediates.
Who are the key members and board of directors at Keminterpharm Spechem Resources?
Financial Performance of Keminterpharm Spechem Resources.
Keminterpharm Spechem Resources Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 1301.45% increase. The company also saw a substantial improvement in profitability, with a 4346.67% increase in profit. The company's net worth Soared by an impressive increase of 168.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Keminterpharm Spechem Resources?
In 2020, Keminterpharm Spechem Resources had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 07 Oct 2021 | ₹2.50 M | Open |
How Many Employees Work at Keminterpharm Spechem Resources?
Unlock and access historical data on people associated with Keminterpharm Spechem Resources, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Keminterpharm Spechem Resources, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Keminterpharm Spechem Resources's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
